Commercial Credit Report for Cipla Ltd (Parent)

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Cipla Ltd (Parent) is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Cipla Ltd (Parent)
Mumbai Central
Phone: +91 2224826000p:+91 2224826000	MUMBAI, 400013 India	Fax: +91 2224826120f:+91 2224826120

Business Summary

Cipla Limited is an India-based company, which is primarily engaged in the business of pharmaceuticals. The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. The Company's product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The Company's geographical segments include India, the United States, South Africa, and Rest of the World. The Company has its network of manufacturing, trading and other incidental operations in India and International markets. The Company has approximately 47 manufacturing sites.

(Source: ARS)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
-	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
6/30/2023	3/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations
3841	Surgical and medical instruments and apparatus
2833	Medicinal chemicals and botanical products
6719	Offices of holding companies, not elsewhere classified

Officers and Directors

Title	Name	Age	Title Date	Start Date
Non-Executive Chairman of the Board	Yusuf K.Hamied		1/1/2016	1/1/1976
Global Chief Executive Officer, Managing Director, Executive Director	UmangVohra	50	9/1/2016	8/12/2016
Executive Vice Chairman of the Board	SaminaHamied	47	9/1/2016	7/10/2015
12 additional Officers and Directors records available in full report.

General Information

Outstanding Shares:	807,317,478	(As of 9/11/2023)
Fax Number:	+91 2224826120

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN